Herbalife Nutrition Ltd vs Revvity Inc — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 12.7× Herbalife Nutrition Ltd's market cap, and Revvity Inc pays a 0.18% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Revvity Inc for 12 Days on average.
| HLF | RVTY | |
|---|---|---|
Market Cap | $1.34B | $16.98B |
Volume | 1,589,457 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $157.36 |
52-Week Low | $7.75 | $82.26 |
Typical Hold Time | 43 Days | 12 Days |
Enterprise Value | $3.18B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →